Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Invested Capital (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Invested Capital readings, the most recent being $14.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 49.76% year-over-year to $14.9 million, compared with a TTM value of $14.9 million through Dec 2025, down 49.76%, and an annual FY2025 reading of $14.9 million, down 49.76% over the prior year.
  • Invested Capital hit $14.9 million in Q4 2025 for Lisata Therapeutics, down from $17.4 million in the prior quarter.
  • The five-year high for Invested Capital was $60.7 million in Q1 2023, with the low at $14.9 million in Q4 2025.
  • Median Invested Capital over the past 3 years was $35.7 million (2024), compared with a mean of $36.7 million.
  • The sharpest move saw Invested Capital decreased 29.59% in 2024, then tumbled 49.76% in 2025.
  • Year by year, Invested Capital stood at $47.9 million in 2023, then crashed by 38.26% to $29.6 million in 2024, then plummeted by 49.76% to $14.9 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $14.9 million, $17.4 million, and $20.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.